Hepatic Insufficiency clinical trials

The registry lists 113 studies for Hepatic Insufficiency across more than 10 countries. 15 are recruiting or about to start. 85 of them are mainly about Hepatic Insufficiency (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-01. Counting its 5 narrower conditions too, such as Hepatic Encephalopathy: 844 studies, 193 open.

Get an email when these change. Save the Hepatic Insufficiency studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 83
Recruiting: 9
Status unknown: 7
Not yet recruiting: 6
Terminated: 6
Withdrawn: 1

Phase

Phase 1: 80
Phase 4: 6
Phase 3: 4
Phase 2: 4

Where

United States: 52
Germany: 14
China: 8
France: 8
Spain: 6
Hungary: 6

Who runs them

Boehringer Ingelheim (13) · Eli Lilly and Company (12) · Merck Sharp & Dohme LLC (10) · Pfizer (5) · Bristol-Myers Squibb (4) · Bayer (3) · University Hospital, Gentofte, Copenhagen (2) · Ahon Pharmaceutical Co., Ltd. (2)

What is being tested here

Drugs under test in Hepatic Insufficiency studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Prednisolone	1	1	2
KRAS G12D Inhibitor INCB161734	1	0	1
Ulonivirine	1	0	1
MDR-001	1	0	1
Brenipatide	1	0	1
Solizmestrocel	1	0	1
Atirmociclib	1	0	1
CDK2 Inhibitor INCB123667	1	0	1
Eloralintide	1	0	1
Acetylcysteine	1	1	1

Drug classes tested here Reverse transcriptase inhibitors 1 open · Tyrosine kinase inhibitors (TKIs) 11

Coming up

2phase 3 studies under way

6studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6

Nov 2026A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment · Eli Lilly and Company
Mar 2027A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. · Eli Lilly and Company
Mar 2027A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment · Incyte Corporation
Apr 2027A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment · Incyte Corporation
Jun 2027Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014) · Merck Sharp & Dohme LLC
Aug 2027A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease · Pfizer

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 (33%) set no upper age limit and 3 (33%) stop at 75 or younger. 1 (11%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (44%) take healthy volunteers.

Recruiting studies that take each age, of 9
Age	Women	Men
10	0 (0%)	0 (0%)
18	8 (89%)	8 (89%)
30	8 (89%)	8 (89%)
40	8 (89%)	8 (89%)
50	8 (89%)	8 (89%)
65	8 (89%)	8 (89%)
75	7 (78%)	7 (78%)
85	5 (56%)	5 (56%)

Across all 113 studies, recruiting or not: 53% stop at 75 or younger and 8% at 65; 3% take children; 2% are for women only and 1% for men only; 65% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hepatic Insufficiency studies take

Of 41 phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	8 mo5–17 · 41 studies	8 mo5–17 · 38 studies	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 113. Browse all 113 → or search them.